Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer

Table 5

Association between PRDX expression and OS in GC patients with different treatment strategies.

PRDXs	Treatment strategies	Cases	Low	High	HR (95% CI)	value
PRDX1	Surgery alone	380	190	190	0.76 (0.57–1.01)	0.057
	5-FU-based adjuvant	153	76	77	1.21 (0.86–1.71)	0.268
	Other adjuvants	76	38	38	0.67 (0.27–1.64)	0.374
PRDX2	Surgery alone	380	190	190	0.72 (0.54–0.96)	0.025
	5-FU-based adjuvant	153	76	77	0.68 (0.48–0.97)	0.030
	Other adjuvants	76	38	38	0.61 (0.25–1.50)	0.276
PRDX3	Surgery alone	380	190	190	0.74 (0.55–0.99)	0.038
	5-FU-based adjuvant	153	76	77	1.20 (0.85–1.69)	0.296
	Other adjuvants	76	38	38	0.94 (0.39–2.26)	0.883
PRDX4	Surgery alone	380	190	190	0.85 (0.64–1.14)	0.275
	5-FU-based adjuvant	153	76	77	0.78 (0.56–1.11)	0.164
	Other adjuvants	76	38	38	1.01 (0.42–2.43)	0.990
PRDX5	Surgery alone	380	191	189	0.82 (0.62–1.10)	0.187
	5-FU-based adjuvant	34	17	17	0.94 (0.38–2.33)	0.893
	Other adjuvants	76	38	38	0.48 (0.19–1.20)	0.110
PRDX6	Surgery alone	380	190	190	1.04 (0.78–1.38)	0.795
	5-FU-based adjuvant	153	76	77	0.98 (0.70–1.38)	0.913
	Other adjuvants	76	38	38	1.16 (0.48–2.80)	0.738